BioMarin to restrict hemophilia therapy to three countries, seeking to overcome slow sales

Struggling to find new patients, BioMarin Pharmaceuticals on Monday said it would restrict sales of its gene therapy for hemophilia A to three countries where it is currently approved, including the United States — a restructuring intended to reduce costs and help the treatment become profitable by next year.

The one-time treatment called Roctavian was approved in Europe in 2022 and in the U.S. in 2023. But in the second quarter, the company treated only five patients, generating $7 million in sales.

Under the new marketing plan, BioMarin will sell Roctavian in the U.S., Germany, and Italy, where it is currently approved and reimbursed. The company anticipates reducing Roctavian-related expenses to $60 million per year by 2025 and for the treatment to become profitable by the end of 2025.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In